Vanguard Asset Management
MLTX icon

Vanguard Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vanguard Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$705K Buy
36,195
+12,367
+52% +$224K ﹤0.01% 2048
2026
Q1 		$444K Buy
+23,828
New +$395K ﹤0.01% 2150

Other funds holding MLTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Asset Management's MLTX Position: Q2 2026 in Review

Vanguard Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 52% in Q2 2026, buying an estimated $224K and bringing the position to 36,195 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #2048.

Vanguard Asset Management first reported a position in MLTX in Q1 2026 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Vanguard Asset Management held 36,195 shares of MoonLake Immunotherapeutics worth $705K as of Q2 2026.
  • Vanguard Asset Management bought 12,367 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $224K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2048 holding.
  • Vanguard Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.